MiNK Q2 net loss $6.1M; cash $29.8M; DARPA selects AgenT-797; clinical data updates expected 2H22

MiNK Therapeutics, Inc.

2022-Q2 EPS reported -$0.41

Cash $29.8M as of June 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $4.6M for Q2.
Net loss $6.1M ($0.18/share) vs $6.3M ($0.26/share) in Q2 2021; R&D spend $5.9M vs $3.6M.
AgenT-797 clinical data updates in solid tumors, myeloma and viral ARDS planned for 2H2022.
AgenT-797 identified as selectable for DARPA funding; contract negotiations underway.
Internal cGMP manufacturing completed with capacity to treat >700,000 patients/year; Dr. Joy Zhou appointed VP CMC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.